Literature DB >> 10715673

Efficacies of 5- and 14-day primaquine regimens in the prevention of relapses in Plasmodium vivax infections.

N J Gogtay1, S Desai, K D Kamtekar, V S Kadam, S S Dalvi, N A Kshirsagar.   

Abstract

Vivax malaria accounts for 80% of malaria cases in Mumbai (Bombay) and has high morbidity. In India, the standard treatment to prevent relapses of vivax malaria is a 5-day regimen of primaquine. However, between 1977 and 1997, the efficacy of this treatment declined from approximately 99% to 87%. The efficacy of the 5-day regimen was therefore compared with that of the 14-day regimen currently recommended by the World Health Organization, in Mumbai. The relapse rates observed, over a 6-month period of follow-up, were 0% with the 14-day regimen, 26.7% with the 5-day, and 11.7% when no primaquine treatment was given. The expenditure incurred on the door-to-door dispensing of the 5-day regimen appears to be without benefit. There is an urgent need to review the present strategy for controlling relapses in vivax malaria, at least for the city of Mumbai, and similar studies need to be carried out in other parts of India, to make all anti-relapse strategies more appropriate.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10715673     DOI: 10.1080/00034989957790

Source DB:  PubMed          Journal:  Ann Trop Med Parasitol        ISSN: 0003-4983


  23 in total

Review 1.  8-Aminoquinoline Therapy for Latent Malaria.

Authors:  J Kevin Baird
Journal:  Clin Microbiol Rev       Date:  2019-07-31       Impact factor: 26.132

Review 2.  Resistance to therapies for infection by Plasmodium vivax.

Authors:  J Kevin Baird
Journal:  Clin Microbiol Rev       Date:  2009-07       Impact factor: 26.132

3.  RADICAL CURE OF VIVAX MALARIA : 5 OR 14 DAYS.

Authors:  K M Hassan; M K Gosh
Journal:  Med J Armed Forces India       Date:  2011-07-21

4.  Malaria and National Vector Borne Disease Control Programme.

Authors:  Rajni Sharma; Ashok Kumar Dutta
Journal:  Indian J Pediatr       Date:  2011-09-10       Impact factor: 1.967

5.  Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia.

Authors:  Inge Sutanto; Bagus Tjahjono; Hasan Basri; W Robert Taylor; Fauziah A Putri; Rizka A Meilia; Rianto Setiabudy; Siti Nurleila; Lenny L Ekawati; Iqbal Elyazar; Jeremy Farrar; Herawati Sudoyo; J Kevin Baird
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

Review 6.  Determinants of relapse periodicity in Plasmodium vivax malaria.

Authors:  Nicholas J White
Journal:  Malar J       Date:  2011-10-11       Impact factor: 2.979

7.  Prospective Study of Plasmodium vivax Malaria Recurrence after Radical Treatment with a Chloroquine-Primaquine Standard Regimen in Turbo, Colombia.

Authors:  Lina Zuluaga-Idárraga; Silvia Blair; Sheila Akinyi Okoth; Venkatachalam Udhayakumar; Paula L Marcet; Ananias A Escalante; Neal Alexander; Carlos Rojas
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

8.  Multiple-clone activation of hypnozoites is the leading cause of relapse in Plasmodium vivax infection.

Authors:  Flávia Carolina F de Araujo; Antônio Mauro de Rezende; Cor Jesus F Fontes; Luzia Helena Carvalho; Cristiana F Alves de Brito
Journal:  PLoS One       Date:  2012-11-21       Impact factor: 3.240

9.  The potential elimination of Plasmodium vivax malaria by relapse treatment: insights from a transmission model and surveillance data from NW India.

Authors:  Manojit Roy; Menno J Bouma; Edward L Ionides; Ramesh C Dhiman; Mercedes Pascual
Journal:  PLoS Negl Trop Dis       Date:  2013-01-10

Review 10.  Primaquine radical cure of Plasmodium vivax: a critical review of the literature.

Authors:  George K John; Nicholas M Douglas; Lorenz von Seidlein; Francois Nosten; J Kevin Baird; Nicholas J White; Ric N Price
Journal:  Malar J       Date:  2012-08-17       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.